Cadrenal Therapeutics Eyes $1B+ CSA-AKI Market After Competitor’s Phase 3 Failure
Event summary
- Cadrenal Therapeutics is advancing CAD-1005 for both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).
- A competitor’s Phase 3 trial for CSA-AKI was discontinued due to lack of efficacy, highlighting the $1B+ market opportunity.
- CAD-1005 demonstrated a >25% reduction in thrombotic events and favorable safety data in Phase 2 trials presented at ISTH 2026 Congress.
The big picture
Cadrenal Therapeutics is capitalizing on a critical gap in the acute care market following a competitor’s Phase 3 failure, positioning its 12-LOX inhibitor as a first-in-class solution for CSA-AKI. The company’s dual-indication strategy for CAD-1005 aligns with broader industry trends toward targeted therapies addressing root causes of cardio-renal injury.
What we're watching
- Regulatory Momentum
- Whether CAD-1005’s Orphan Drug and Fast Track designations will accelerate its path to Phase 3 trials.
- Partnering Potential
- The pace at which Cadrenal secures strategic partnerships for out-licensing or co-development of CAD-1005.
- Competitive Advantage
- How the discontinuation of a competitor’s Phase 3 trial will impact market positioning and investor confidence in CAD-1005.